Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | AGXT | P21549 | 1/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 2/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.39 |
| ▸ | CFD | P00746 | 1/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12261662 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4MAOARXRARXRB | |
| SCHEMBL13701300 | 0.87 | SLC6A4 (0.39) | RXRARXRBRXRGSLC6A4CYP17A1 | |
| SCHEMBL5712566 | 0.83 | SLC6A4 (0.48) | LMNASLC6A4SCN4AANPEPENPEP | |
| SCHEMBL11296454 | 0.82 | SLC6A4 (0.53) | CHRNB2CHRNA4LMNASLC6A4CYP17A1 | |
| SCHEMBL170928 | 0.81 | SLC6A4 (0.56) | LMNASLC6A4SCN4A | |
| SCHEMBL176808 | 0.81 | SLC6A4 (0.56) | LMNASLC6A4SCN4A | |
| Benzene SCHEMBL28170835 | 0.81 | SLC6A4 (0.56) | LMNASLC6A4SCN4A | |
| SCHEMBL43945 | 0.81 | SLC6A4 (0.56) | LMNASLC6A4SCN4A | |
| SCHEMBL29503095 | 0.81 | SLC6A4 (0.56) | LMNASLC6A4SCN4A | |
| SCHEMBL3159983 | 0.79 | TAAR1 (0.48) | CHRNB2CHRNA4MAOASLC6A4AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1509497-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | Amgen Inc. (US) | 2005-03-02 | — | — | EP | claimed |
| WO-2003099776-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | AMGEN INC. (US) | 2003-12-04 | — | — | WO | claimed |
| EP-2010150-A2 | STABLE EMULSION FORMULATIONS | Amgen Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007124465-A2 | STABLE EMULSION FORMULATIONS | AMGEN INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| EP-1509497-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | Amgen Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003099776-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| US-6124305-A | TREATING NON-INSULIN DEPENDENT DIABETES MELLITUS | NOVARTIS AG (CH) | 2000-09-26 | — | — | US | disclosed |
| US-6011155-A | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV | NOVARTIS AG (CH) | 2000-01-04 | — | — | US | disclosed |